Trovagene Inc. (NASDAQ:TROV) shares dropped 4.4% during trading on Monday . The company traded as low as $4.81 and last traded at $4.83, with a volume of 138,613 shares changing hands. The stock had previously closed at $5.05.

TROV has been the topic of a number of research reports. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Trovagene in a report on Monday, March 28th. Leerink Swann lowered Trovagene from an “outperform” rating to a “sector perform” rating in a report on Tuesday, April 26th. Avondale Partners reaffirmed a “market perform” rating and issued a $6.00 price objective on shares of Trovagene in a report on Tuesday, March 29th. Maxim Group initiated coverage on Trovagene in a report on Wednesday, July 6th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, Zacks Investment Research raised Trovagene from a “sell” rating to a “hold” rating in a report on Wednesday, July 13th. Seven research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $6.96.

The company’s market capitalization is $146.92 million. The firm’s 50 day moving average price is $4.78 and its 200-day moving average price is $4.78.

Trovagene (NASDAQ:TROV) last announced its earnings results on Tuesday, May 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.07. Analysts anticipate that Trovagene Inc. will post ($1.30) earnings per share for the current year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.